[Effectiveness of immunostimulants in nonspecific ulcerative colitis].
Perederiĭ. V G VG; Tkach. S M SM; Bychkova. N G NG; Blazhenko. I L IL
Key Findings
- Thymalin and sodium nucleinate together gave the strongest clinical and immune improvements
- The benefit was biggest in patients with mild disease
- Levamisole caused frequent side effects and offered no clear advantage
Practical Outcomes
- For biohackers interested in gut‑immune health, thymalin may be worth exploring as an immune‑boosting supplement for mild inflammatory conditions, but the study doesn’t provide dosing details or evidence for broader longevity benefits. Use cautiously and consider that the data are limited to ulcerative colitis patients.
Summary
The study found that the thymus‑derived peptide thymalin, especially when combined with sodium nucleinate, helped improve symptoms and immune markers in people with mild ulcerative colitis, while another drug, levamisole, caused more side effects and didn’t add extra benefit.
Abstract
Clinical and immunologic efficacies of some immunostimulants (levamisole, sodium nucleinate, thymic preparations) included in therapeutic schemes in nonspecific ulcerous colitis both separately and in various combinations were under study. The efficacy of these stimulants was found to depend on the disease severity and proved to be the highest in the light course. Thymalin and sodium nucleinate showed the highest clinical and immunologic efficacies, particularly if used together. Levamisole administration was associated with frequent side effects and had no essential advantages over basic therapy. This permits a conclusion that immunostimulants are pathogenetically validated in therapy of ulcerous colitis, for they result in reduction or elimination of immunity insufficiency and their administration leads to a positive clinical effect in the majority of cases.
Study Information
pubmed
1990